Unlike ER-positive luminal tumors and HER2-positive tumors that show a more favorable prognosis partially due to anti-hormone therapy responsiveness, the lack of expression of the molecular targets is associated with the highest recurrence rate and the worst overall survival rate among all the breast cancer subtypes. This evidence concerns the gene ERBB2 and breast cancer.